Crossmark

Teplizumab for stage 2 type 1 diabetes: a new era in pediatric diabetes prevention

Crossref DOI link: https://doi.org/10.1007/s00431-025-06520-y

Published Online: 2025-10-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zaitoon, Doaa

Zaitoon, Hussein https://orcid.org/0000-0002-4979-3799
License Information

Text and Data Mining valid from 2025-10-08

Version of Record valid from 2025-10-08
More Information

Article History

Received: 3 August 2025

Revised: 14 September 2025

Accepted: 24 September 2025

First Online: 8 October 2025

Declarations

:

: The authors declare no competing interests.